Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | ESR1 | P03372 | 2/20 | 0.58 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 4/20 | 0.54 |
| ▸ | CA12 | O43570 | 2/20 | 0.54 |
| ▸ | CA9 | Q16790 | 2/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.54 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.50 |
| ▸ | UQCRB | P14927 | 1/20 | 0.50 |
| ▸ | ELANE | P08246 | 1/20 | 0.50 |
| ▸ | MMP3 | P08254 | 1/20 | 0.48 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.48 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3235446 | 1.00 | GAA (0.59) | GAAPKMESR1ESR2LMNA | |
| SCHEMBL10395680 | 1.00 | GAA (0.59) | GAAPKMESR1ESR2LMNA | |
| SCHEMBL811302 | 1.00 | GAA (0.59) | GAAPKMESR1ESR2LMNA | |
| SCHEMBL5311344 | 1.00 | GAA (0.59) | GAAPKMESR1ESR2LMNA | |
| SCHEMBL18838 | 0.92 | GAA (0.67) | GAAPKMLMNACA2CA12 | |
| SCHEMBL3792342 | 0.92 | GAA (0.67) | GAAPKMLMNACA2CA12 | |
| SCHEMBL29724901 | 0.92 | GAA (0.67) | GAAPKMLMNACA2CA12 | |
| SCHEMBL124022 | 0.92 | GAA (0.67) | GAAPKMLMNACA2CA12 | |
| SCHEMBL7935388 | 0.91 | HTR6 (0.61) | GAAPKMESR1ESR2LMNA | |
| SCHEMBL7929206 | 0.91 | MMP3 (0.65) | GAAPKMESR1LMNACA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE47556-E1 | Optical element compound, optical material, and optical element | CANON KABUSHIKI KAISHA (JP) | 2019-08-06 | — | — | US | disclosed |
| EP-2390684-B1 | OPTICAL ELEMENT COMPOUND, OPTICAL MATERIAL, AND OPTICAL ELEMENT | CANON KK (JP) | 2019-04-24 | — | — | EP | disclosed |
| US-RE47000-E1 | Optical element compound, optical material, and optical element | CANON KABUSHIKI KAISHA (JP) | 2018-08-21 | — | — | US | disclosed |
| US-8829230-B2 | Optical element compound, optical material, and optical element | CANON KABUSHIKI KAISHA (JP) | 2014-09-09 | — | — | US | disclosed |
| US-20140031582-A1 | OPTICAL ELEMENT COMPOUND, OPTICAL MATERIAL, AND OPTICAL ELEMENT | CANON KABUSHIKI KAISHA (JP) | 2014-01-30 | — | — | US | disclosed |
| US-8569541-B2 | Optical element compound, optical material, and optical element | CANON KABUSHIKI KAISHA (JP) | 2013-10-29 | — | — | US | disclosed |
| EP-2390684-A2 | Optical element compound, optical material, and optical element | Canon Kabushiki Kaisha (JP) | 2011-11-30 | — | — | EP | disclosed |
| US-20110288330-A1 | OPTICAL ELEMENT COMPOUND, OPTICAL MATERIAL, AND OPTICAL ELEMENT | CANON KABUSHIKI KAISHA (JP) | 2011-11-24 | — | — | US | disclosed |
| US-20110257146-A1 | Method of Treating Kcnq Related Disorders Using Organozinc Compounds | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257146-A1 | Method of Treating Kcnq Related Disorders Using Organozinc Compounds | KCNQ3, KCNQ1, KCNQ5 | GAA 2147/4885PKM 234/4885ESR1 3810/4885 |
| US-20110288330-A1 | OPTICAL ELEMENT COMPOUND, OPTICAL MATERIAL, AND OPTICAL ELEMENT | CENPE, AXIN2, CCNE2 | GAA 977/4885PKM 2719/4885ESR1 476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.